This link here: Te Aho o Te Kahu – Cancer during COVID-19 contains information for patients and whānau with cancer. Cancer treatment continues at all phases of the Ministry of Health’s Omicron Response Plan.Continue Reading
In a radio interview today, Health Minister Andrew Little said the final Pharmac Review report will be publicised “in a matter of a few weeks.”The Pharmac Review panel was expected to hand over the final report to Minister Little by 28 February 2022 – he received it last week.Click below to listen to the interview on...Continue Reading
Dear All, I am writing this today and hearing about the 20,000 plus daily Covid-19 cases being reported which we know is probably half of the real numbers. This issue will be of utmost concern to all of us who are immuno- compromised so endeavour to keep safe. Since my last letter, I have managed...Continue Reading
Last Thursday 24 February the ICBCC Policy Strategy Working Group met to discuss on the Policy Strategy to address the specific impact of the pandemic on immunocompromised blood cancer patients (both acute and chronic) in a workshop-style setting. The meeting was facilitated by our partner Patvocates. During the 2 hour workshop the group managed to define...Continue Reading
The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to pomalidomide–dexamethasone in relapsed and refractory multiple myeloma. Here, we report a prespecified updated overall survival analysis at 24 months after the primary analysis. Methods In this randomised, multicentre, open-label, phase 3 study adult patients (aged ≥18 years) with relapsed...Continue Reading
Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitors, according to a two-year, follow-up analysis of the ICARIA-MM study However the CD38-directed monoclonal antibody may find it difficult to make its mark in the Australian setting any time soon. The study, published...Continue Reading
Watch this excellent presentation by Dr Rob Weinkove of the Malaghan Institute, courtesy of Leukaemia & Blood Cancer NZ, on ‘COVID-19 and haematology patients – protecting yourself in 2022’.Continue Reading
UPCOMING PATIENT MEETING You’re invited to join us at our next Wellington Patient Meeting Thursday 1st July 2021, 5pm BNZ Partners Centre, Level 10, Ricoh House1 Victoria StreetWellington 6011 Patients and their supporters are welcome to join the trustees for light refreshments and a brief presentation related to issues affecting patients and carers living with...Continue Reading
DREAMM 7 – A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belnatamab mafadotin (GSK2857916), Bortezomib, and Dexamethasone Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma Recruitment to start from end of September (Phase III study from GSK) Information and how to...Continue Reading
